BMS reports liver injury events in lung disease program, with key readout near

Phase 3admilparantNegative

AI Analysis

Summary

Bristol Myers Squibb will soon release Phase 3 data for admilparant in lung disease, but reports of a death due to liver injury in the program raise safety concerns about the drug class and could impact its competitive position against Contineum Therapeutics' rival product.

Clinical Trial Data

Phase

Phase 3

Outcome Details

data readout pending; reports of liver injury death in program raise safety concerns

Importance:7/10

Sentiment:

-0.60

Phase 3lung diseasesafety concernliver injuryregulatory risk

Related Companies

$BMY

Read the original article

Published by BioSpace on October 1, 2026 2:57 PM

Read Original